Bristol Myers Squibb’s Cobenfy failed to outdistance a placebo in a Phase 3 test that evaluated the drug as an adjunct to antipsychotics in schizophrenia patients. ... Karuna Therapeutics.

Bristol Myers obtained the drug, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics, and is seen as one of the key growth drivers for the drugmaker.

Cobenfy’s therapeutic properties were discovered through “serendipitous observation,” said Dr. Steve Paul, ... Karuna Therapeutics, that developed the drug. ...

Cobenfy’s therapeutic properties were discovered through “serendipitous observation,” said Dr. Steve Paul, ... Karuna Therapeutics, that developed the drug. ...

Sales of Cobenfy, a new mind-stabilizing medicine, totaled $10 million in the final months of last year, results that fell in line with analyst expectations. Bristol Myers Squibb, which acquired ...

Alzheimer Disease. One of the drugs mentioned in the report is xanomeline/tropsium chloride (Cobenfy; Karuna Therapeutics, acquired by Bristol Myers Squibb), used to treat patients with ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis ... $14 billion acquisition of biotech company Karuna Therapeutics at the ...